2-Butanol API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
2-Butanol | CAS No: 78-92-2 | GMP-certified suppliers
A medication that serves as an investigational fatty alcohol API potentially relevant for research in lipid-related applications and experimental pharmaceutical formulation development.
Therapeutic categories
Product Snapshot
- 2-Butanol is a small molecule typically used in liquid formulations
- It is primarily investigated for its potential applications in pharmaceutical synthesis and excipient roles rather than direct therapeutic use
- Currently, 2-Butanol status is experimental and investigational, with no approvals from major regulatory agencies such as the FDA or EMA
Clinical Overview
There is no established clinical indication for 2-butanol, and it remains an experimental or investigational compound without approved therapeutic applications. Pharmacodynamic properties and mechanism of action have not been characterized within clinical or regulatory frameworks.
From a pharmacokinetic perspective, detailed absorption, distribution, metabolism, and excretion (ADME) data for 2-butanol are not available through currently accessible sources. As a small, moderately lipophilic secondary alcohol, it is anticipated to possess physicochemical properties allowing for moderate systemic distribution and metabolic transformation, likely mediated by typical alcohol dehydrogenase pathways, though this remains to be substantiated.
Safety and toxicity profiles for 2-butanol are not comprehensively delineated in approved pharmaceutical references, though structurally related secondary alcohols can exhibit central nervous system depressant effects and potential toxicity at sufficient exposure levels. Thus, safety assessments and toxicological studies would be essential for any intended pharmaceutical application.
No notable pharmaceutical brand names or marketed formulations incorporating 2-butanol are reported. Its role is primarily confined to research and investigational use.
When sourcing 2-butanol as an active pharmaceutical ingredient (API), attention to purity standards, residual solvent limits, and batch-to-batch consistency is crucial. Compliance with regulatory guidelines for organic solvents and secondary alcohols, as well as robust supply chain traceability, are key quality considerations to support experimental or formulation development activities.
Identification & chemistry
| Generic name | 2-Butanol |
|---|---|
| Molecule type | Small molecule |
| CAS | 78-92-2 |
| UNII | DLH38K423J |
| DrugBank ID | DB02606 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| NADP-dependent isopropanol dehydrogenase | Thermoanaerobacter brockii |
Formulation & handling
- 2-Butanol is a small molecule suitable for oral formulation due to moderate water solubility and low lipophilicity.
- Being a secondary alcohol, it may require protection from oxidation and moisture during handling and storage.
- Its experimental status necessitates thorough stability and compatibility assessments in formulation development.
Regulatory status
2-Butanol is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
